Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$89.7 million.

  • Agios Pharmaceuticals' Free Cash Flow fell 598.91% to -$89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.1 million, marking a year-over-year decrease of 2543.97%. This contributed to the annual value of -$391.5 million for FY2024, which is 3179.99% down from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Free Cash Flow stood at -$89.7 million, which was down 598.91% from -$78.0 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Free Cash Flow high stood at -$62.0 million for Q3 2023, and its period low was -$134.1 million during Q4 2024.
  • Over the past 5 years, Agios Pharmaceuticals' median Free Cash Flow value was -$85.2 million (recorded in 2021), while the average stood at -$89.3 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Free Cash Flow surged by 3521.09% in 2022, and later tumbled by 8444.76% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Free Cash Flow stood at -$88.6 million in 2021, then grew by 25.19% to -$66.3 million in 2022, then decreased by 9.73% to -$72.7 million in 2023, then plummeted by 84.45% to -$134.1 million in 2024, then soared by 33.12% to -$89.7 million in 2025.
  • Its Free Cash Flow stands at -$89.7 million for Q3 2025, versus -$78.0 million for Q2 2025 and -$112.3 million for Q1 2025.